Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by bball67on Jul 14, 2021 2:14pm
100 Views
Post# 33543259

RE:RE:Promis financing

RE:RE:Promis financingAs, a long time investor I am disappointed and skeptical as well. But, lets acknowledge that change is happening. I have been involved with venture financing, IPO and secondary offering. The bankers I met were incredibly motivated and hard working. Assuming the Boston Group backs and leads an offering, they have the attention of maybe a dozen different banking firms. A whole new crew of bankers will likely be involved in raising a relatively small amount of money and they don't have to spend a month on a prospectus, it's done. Also, if an investor see's the resume's of the various Boston Group investors and learns how much they are willing to put in, they will be in. The bankers have no time for vacation in such a hot market. Bought more Promis stock today. They are giving it away.
<< Previous
Bullboard Posts
Next >>